Aliya Lakhani
VC Associate, Chemical Engineer, and Biotech Researcher
Summary
Aliya Lakhani is an accomplished scientist and engineer with a strong background in chemical and biomolecular engineering, holding a Ph.D. from UCLA and B.S./M.S.E. degrees from Johns Hopkins University. Her academic research focused on cutting-edge topics such as metabolomics and isotope tracing for CAR T cell and cancer cell biology, demonstrating her expertise in biochemical processes and their application to healthcare challenges. digitaldxventures+3
Transitioning from academia, Aliya has made a significant pivot into venture capital, serving as an Associate at Precursor Ventures. In this role, she leverages her scientific rigor and analytical skills to source, diligence, and support early-stage founders, particularly those in the biotech and healthcare sectors, showcasing her ability to apply deep technical knowledge to investment strategies. precursorvc+3
Her professional experience includes hands-on roles in both pharmaceutical R&D at MedImmune/AstraZeneca, where she contributed to upstream process development, and clinical research at UCSF, where she used advanced imaging techniques to study glioblastomas. Additionally, her fellowship at MedTech Innovator highlights her engagement in the medical technology startup ecosystem through due diligence and market research. digitaldxventures+2
Work
Education
Writing
Extracellular domains of CARs reprogramme T cell metabolism without antigen stimulation
January 1, 2024This research explores how extracellular domains of Chimeric Antigen Receptors (CARs) can influence T cell metabolism independently of antigen stimulation.
Toward systems-level metabolic analysis in endocrine disorders and cancer
January 1, 2023This work aims to advance systems-level metabolic analysis for a better understanding of endocrine disorders and cancer.
Integrative metabolic flux analysis reveals an indispensable dimension of phenotypes
January 1, 2022This paper highlights the importance of integrative metabolic flux analysis in understanding phenotypes, revealing crucial dimensions in biological systems.
MR-detectable metabolic biomarkers of response to mutant IDH inhibition in low-grade glioma
January 1, 2020This study investigates metabolic biomarkers detectable by Magnetic Resonance (MR) that indicate the response to mutant IDH inhibition in low-grade glioma.